Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline

Little, Karis; Llorián-Salvador, María; Scullion, Sarah; Hernández, Cristina; Simó‐Servat, Olga; Marco, Angel Del; Bosma, Esmeralda K.; Vargas-Soria, Maria; Carranza-Naval, Maria Jose; Bergen, Tine Van; Galbiati, Silvia; Viganò, Ilaria; Musi, Clara Alice; Schlingemann, R; Feyen, Jean H.M.; Borsello, Tiziana; Zerbini, Gianpaolo; Klaassen, Ingeborg; García-Alloza, Mónica; Simó, Rafael; Stitt, Alan W.

doi:10.1016/j.tem.2021.10.008

Cited by 56 publications

(28 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reports indicate that a history of amputation or ulceration, 68 peripheral edema, 69 foot pressure, 70 plantar callus formation, 71 nephropathy, 72 poor glucose control, 73 ischemia, 74 retinopathy 75 and prolonged diabetes 76 is an important predisposing factor leading to the development of DFUs. Recent studies have reported that diabetic wounds exhibit a prolonged inflammatory phase due to impairment of phagocytes and macrophages, resulting in the excessive release of MMPs (matrix metalloproteinases), causing degradation of collagen and extracellular matrix (ECM).…”

Section: Pathophysiology Of Diabetic Foot Ulcers (Dfus)mentioning

confidence: 99%

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Pathophysiology Of Diabetic Foot Ulcers (Dfus)mentioning

confidence: 99%

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thus, the presence of DR has been associated with the development of macrovascular complications of diabetes, specifically, cerebrovascular complications, cardiovascular complications and vascular peripheral complications [ 4 ]. Moreover, the evaluation of retinal neurodegeneration could help to identify patients which are at risk of cognitive impairment, an emerging complication of the type 2 diabetes [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

New Insights into Treating Early and Advanced Stage Diabetic Retinopathy

Simó

Hernández

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is the leading cause of preventable blindness in the working-age population. The disease progresses slowly, and we can roughly differentiate two stages: early-stage (ESDR), in which there are mild retinal lesions and visual acuity is generally preserved, and advanced-stage (ASDR), in which the structural lesions are significant and visual acuity is compromised. At present, there are no specific treatments for ESDR and the current recommended action is to optimize metabolic control and maintain close control of blood pressure. However, in the coming years, it is foreseeable that therapeutic strategies based in neuroprotection will be introduced in the clinical arena. This means that screening aimed at identifying patients in whom neuroprotective treatment might be beneficial will be crucial. Regarding the treatment of ASDR, the current primary course is based on laser photocoagulation and intravitreal injections of anti-angiogenic factors or corticosteroids. Repeated intravitreal injections of anti-VEGF agents as the first-line treatment would be replaced by more cost-effective and personalized treatments based on the results of “liquid biopsies” of aqueous humor. Finally, topical administration (i.e., eye drops) of neuroprotective, anti-inflammatory and anti-angiogenic agents will represent a revolution in the treatment of DR in the coming decade. In this article, all these approaches and others will be critically discussed from a holistic perspective.

show abstract

“…BBB breakdown was suggested to be involved in the pathophysiology of several neurological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis [12]. However, the mechanisms driving barrier breakdown and their link to pathophysiology of neurodegenerative diseases are not yet fully characterized [13]. Pre-clinical studies in animal models poorly translate to humans and represent a major hurdle in the drug discovery pipeline, since 80% of potential treatments fail in clinical trials [14].…”

Section: Introductionmentioning

confidence: 99%

Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature

Maurissen

Pavlou

Bichsel

et al. 2022

JPM

View full text Add to dashboard Cite

Blood-neural barriers regulate nutrient supply to neuronal tissues and prevent neurotoxicity. In particular, the inner blood-retinal barrier (iBRB) and blood–brain barrier (BBB) share common origins in development, and similar morphology and function in adult tissue, while barrier breakdown and leakage of neurotoxic molecules can be accompanied by neurodegeneration. Therefore, pre-clinical research requires human in vitro models that elucidate pathophysiological mechanisms and support drug discovery, to add to animal in vivo modeling that poorly predict patient responses. Advanced cellular models such as microphysiological systems (MPS) recapitulate tissue organization and function in many organ-specific contexts, providing physiological relevance, potential for customization to different population groups, and scalability for drug screening purposes. While human-based MPS have been developed for tissues such as lung, gut, brain and tumors, few comprehensive models exist for ocular tissues and iBRB modeling. Recent BBB in vitro models using human cells of the neurovascular unit (NVU) showed physiological morphology and permeability values, and reproduced brain neurological disorder phenotypes that could be applicable to modeling the iBRB. Here, we describe similarities between iBRB and BBB properties, compare existing neurovascular barrier models, propose leverage of MPS-based strategies to develop new iBRB models, and explore potentials to personalize cellular inputs and improve pre-clinical testing.

show abstract

Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline

Cited by 56 publications

References 222 publications

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario

New Insights into Treating Early and Advanced Stage Diabetic Retinopathy

Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature

Contact Info

Product

Resources

About